Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Mar 15, 2022; 14(3): 568-586
Published online Mar 15, 2022. doi: 10.4251/wjgo.v14.i3.568
Published online Mar 15, 2022. doi: 10.4251/wjgo.v14.i3.568
Table 6 Efficacy of endoscopic eradication therapy for Barrett’s esophagus with submucosal adenocarcinoma
| Ref. | Type | n | Eradication of cancer | Survival |
| Manner et al[81] | Retrospective | 61 | 87% (including HGD) | 5-yr OS 84% |
| Ngamruengphong et al[120] | Retrospective | 39 | - | 5-yr OS 66% |
| Schölvinck et al[78] | Retrospective | 43 | - | Median survival: 46 mo |
| Künzli et al[122] | Retrospective (RFA or APC) | 35 | 100% | - |
| Semenkovich et al[74] | Retrospective | 588 | - | 5-yr OS 50% |
| Otaki et al[77] | Retrospective (RFA/APC/Cryo) | 73 | 63% (including HGD) | 5-yr OS 59% |
- Citation: Choi KKH, Sanagapalli S. Barrett’s esophagus: Review of natural history and comparative efficacy of endoscopic and surgical therapies. World J Gastrointest Oncol 2022; 14(3): 568-586
- URL: https://www.wjgnet.com/1948-5204/full/v14/i3/568.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i3.568